Product news

Share this article:
Mylan received FDA approval for generic versions of AstraZeneca's hypertension treament, Plendil extended-release tablets. Mylan said it received approval for 2.5 mg, 5 mg, and 10 mg doses and already started shipping the product.

Pfizer received approval to market its anti-tumor drug/kinase inhibitor Sutent capsule 12.5 mg (sunitinib malate) in Japan. Sutent is indicated for gastrointestinal stromal tumor after failure of imatinib treatment due to resistance and for renal cell carcinoma not indicated for curative resection and metastatic renal cell carcinoma. Sutent was approved in the US in January 2006.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.